1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Genexine Advances DNA Vaccine With Mid-Stage Cervical Cancer Success

In Regimen With Keytruda

 
• By Ayisha Sharma

The Korean firm’s DNA vaccine has shown promise in a Phase II cervical cancer trial in combination with Merck’s Keytruda, prompting the firm to tout potential in the difficult PD-1 negative group.  

The doctor holds an ampoule with a vaccine. Hand in medical glove. Concept of danger or need for vaccination.
DNA Vaccines Work Similarly To The Better Known mRNA Vaccines • Source: Shutterstock

Genexine Inc.’s first-in-class DNA therapeutic vaccine candidate for HPV-related cancers, GX-188E, has impressed in a challenging cohort of cervical cancer patients in combination with Merck & Co., Inc.’s Keytruda (pembrolizumab) in a mid-stage study.

The Phase II trial enrolled 60 people with advanced HPV 16 – or 18- positive cervical cancer who had progressed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327

 
• By Jessica Merrill

The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”

AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging

 
• By Aakash Babu

The UK major continues to post promising data readouts that further emphasize the safety and efficacy of its blockbuster lung cancer drug, but competition from J&J's Rybrevant is ramping up, and capable challengers are emerging.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: EU tariff deal leaves questions for pharma; Prasad’s CBER exit could bode well for genetic medicines; Winrevair grows but Merck & Co. plans cost cuts; Novo Nordisk selects new CEO; and a look at obesity past the GLP-1s.